Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
SYN's Cash-to-Debt is ranked higher than
94% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. SYN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SYN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
93% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SYN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -12.04
Beneish M-Score: -16.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -568.48
SYN's ROE % is ranked lower than
97% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. SYN: -568.48 )
Ranked among companies with meaningful ROE % only.
SYN' s ROE % Range Over the Past 10 Years
Min: -341.6  Med: -156.43 Max: -48.04
Current: -568.48
-341.6
-48.04
ROA % -135.37
SYN's ROA % is ranked lower than
88% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. SYN: -135.37 )
Ranked among companies with meaningful ROA % only.
SYN' s ROA % Range Over the Past 10 Years
Min: -174.99  Med: -92.6 Max: -41.8
Current: -135.37
-174.99
-41.8
ROC (Joel Greenblatt) % -6621.46
SYN's ROC (Joel Greenblatt) % is ranked lower than
82% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. SYN: -6621.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SYN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14661.9  Med: -915.08 Max: -112.64
Current: -6621.46
-14661.9
-112.64
3-Year EBITDA Growth Rate 15.50
SYN's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SYN: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SYN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -61.2 Max: 101.3
Current: 15.5
0
101.3
3-Year EPS without NRI Growth Rate 2.40
SYN's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. SYN: 2.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SYN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -63.8 Max: 65.1
Current: 2.4
0
65.1
GuruFocus has detected 2 Warning Signs with Synthetic Biologics Inc $SYN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SYN's 10-Y Financials

Financials (Next Earnings Date: 2017-06-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SYN Guru Trades in Q1 2016

Ken Fisher 10,500 sh (unchged)
» More
Q2 2016

SYN Guru Trades in Q2 2016

Ken Fisher 25,000 sh (+138.10%)
» More
Q3 2016

SYN Guru Trades in Q3 2016

Ken Fisher 50,000 sh (+100.00%)
» More
Q4 2016

SYN Guru Trades in Q4 2016

Ken Fisher 133,967 sh (+167.93%)
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CASI, NAS:LIFE, NAS:CTRV, NAS:CERU, NAS:SNSS, OTCPK:CYDY, NAS:EIGR, NAS:CFRX, NAS:AXSM, NAS:ECYT, NAS:ARQL, NAS:VCEL, NAS:CBAY, NAS:GEMP, OTCPK:ORGS, AMEX:XXII, NAS:CXRX, NAS:SBPH, OTCPK:ARTH, NAS:KALV » details
Traded in other countries:SFYB.Germany,
Synthetic Biologics Inc is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases.

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

Ratios

vs
industry
vs
history
PB Ratio 21.21
SYN's PB Ratio is ranked lower than
94% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SYN: 21.21 )
Ranked among companies with meaningful PB Ratio only.
SYN' s PB Ratio Range Over the Past 10 Years
Min: 1.67  Med: 5.72 Max: 14.14
Current: 21.21
1.67
14.14
EV-to-EBIT -1.57
SYN's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. SYN: -1.57 )
Ranked among companies with meaningful EV-to-EBIT only.
SYN' s EV-to-EBIT Range Over the Past 10 Years
Min: -30  Med: -11.9 Max: -1.9
Current: -1.57
-30
-1.9
EV-to-EBITDA -1.58
SYN's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. SYN: -1.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
SYN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -44.1  Med: -12.7 Max: -2.1
Current: -1.58
-44.1
-2.1
Current Ratio 1.09
SYN's Current Ratio is ranked lower than
87% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. SYN: 1.09 )
Ranked among companies with meaningful Current Ratio only.
SYN' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 3.57 Max: 31.55
Current: 1.09
0.17
31.55
Quick Ratio 1.09
SYN's Quick Ratio is ranked lower than
84% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SYN: 1.09 )
Ranked among companies with meaningful Quick Ratio only.
SYN' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 3.57 Max: 31.55
Current: 1.09
0.17
31.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.50
SYN's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SYN: -26.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.4  Med: -4.5 Max: 0
Current: -26.5
-35.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 35.00
SYN's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. SYN: 35.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SYN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.72  Med: 9.62 Max: 38
Current: 35
0.72
38
Price-to-Tangible-Book 21.21
SYN's Price-to-Tangible-Book is ranked lower than
91% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. SYN: 21.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SYN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 8.17 Max: 24.86
Current: 21.21
0.55
24.86
Earnings Yield (Greenblatt) % -63.69
SYN's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. SYN: -63.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SYN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -65.11  Med: 0 Max: 0
Current: -63.69
-65.11
0

More Statistics

EPS (TTM) $ -0.33
Beta2.68
Short Percentage of Float12.57%
52-Week Range $0.69 - 2.74
Shares Outstanding (Mil)117.54

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.43 -0.60 -0.59
EPS without NRI ($) -0.43 -0.60 -0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
SYNTHETIC BIOLOGICS, INC. Financials Mar 08 2017
Synthetic Biologics to Present at the 29th Annual ROTH Conference Mar 07 2017
Synthetic Biologics reports 4Q loss Mar 02 2017
Synthetic Biologics reports 4Q loss Mar 02 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 02 2017
Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results Mar 02 2017
Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2,... Feb 21 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 13 2017
Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference Feb 03 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jan 19 2017
Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to... Jan 18 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
Synthetic Biologics C. Difficile Drug Trial Succeeds Jan 06 2017
Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C.... Jan 05 2017
Synthetic Biologics' C. difficile mid-stage study meets main goal Jan 05 2017
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2017
Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C.... Jan 05 2017
Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference Jan 03 2017
Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed... Dec 13 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 02 2016
Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences Dec 01 2016
Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences Dec 01 2016
Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants Nov 18 2016
Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants Nov 18 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Nov 15 2016
Nokia, Teva Plunge into Tuesday’s 52-Week Low Club Nov 15 2016
Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants Nov 15 2016
Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results Nov 01 2016
Synthetic Biologics to Report Third Quarter 2016 Operational Highlights and Financial Results on... Oct 25 2016
Synthetic Biologics Awarded Research Contract from Centers for Disease Control and Prevention (CDC)... Oct 06 2016
Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial... Sep 20 2016
Synthetic Biologics Reports Second Quarter 2016 Operational Highlights and Financial Results Aug 03 2016
Synthetic Biologics to Report Second Quarter 2016 Operational Highlights and Financial Results on... Jul 26 2016
Synthetic Biologics Announces Granting of European and U.S. Composition of Matter Patents for... Jul 12 2016
Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate... Jul 07 2016
Synthetic Biologics to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference Jul 06 2016
Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the... May 23 2016
Synthetic Biologics to Host Post-DDW 2016® Conference Call to Recap SYN-010 Phase 2 Clinical Trial... May 17 2016
Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of... May 16 2016
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development May 11 2016
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs May 09 2016
Synthetic Biologics to Report First Quarter 2016 Operational Highlights and Financial Results on May... Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)